Division of Hospital Medicine, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee.
Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee.
Hosp Pediatr. 2022 Jul 1;12(7):e230-e237. doi: 10.1542/hpeds.2021-006369.
Penicillin allergy labels are often inaccurate in children and removing unnecessary labels results in improved outcomes and lower health care costs. Although the hospital setting is a frequent point of contact for children, strategies to evaluate penicillin allergies in the hospital are lacking.
We performed a prospective pilot study to determine the feasibility of a centralized, pharmacy-led approach to penicillin allergy evaluation. Children with a reported history of penicillin allergy admitted to our children's hospital were risk-stratified and those stratified as low-risk underwent a single-dose oral challenge by a central pharmacist, regardless of the need for antibiotics. After the completion of each patient's delabeling process, surveys were distributed to health care personnel involved in the patient's care to collect perceptions on the acceptability, appropriateness, and feasibility of this intervention. Measures were scored by using a 5-point Likert scale.
Of the 23 patients who screened as low-risk, 20 underwent a penicillin allergy evaluation and an oral challenge. Of these, the penicillin allergy label was removed in 19 (95%) patients (Fig 1). The median age was 7 years (range 11 months-18 years). Participants rated the risk stratification and delabeling favorably overall, with high ratings on all 3 implementation measures: acceptability (mean 4.55, ± standard deviation [STD] 0.65), appropriateness (mean 4.58, STD ± 0.6), and feasibility (mean 4.51, STD ± 0.73). Measures of acceptability, appropriateness, and feasibility remained high when stratified by health care worker type and provider type.
Our findings provide support for systemic implementation of penicillin allergy delabeling strategies in hospitalized children.
儿童的青霉素过敏标签通常不准确,消除不必要的标签可改善结果并降低医疗保健成本。尽管医院是儿童经常接触的地方,但缺乏在医院评估青霉素过敏的策略。
我们进行了一项前瞻性试点研究,以确定集中式、由药房主导的青霉素过敏评估方法的可行性。我们对我院收治的有青霉素过敏史报告的儿童进行风险分层,低风险的儿童无论是否需要抗生素,均由中心药剂师进行单剂量口服挑战。在完成每位患者的去标签过程后,我们向参与患者护理的医务人员分发调查问卷,以收集他们对这种干预措施的可接受性、适宜性和可行性的看法。通过使用 5 分李克特量表进行评分。
在筛查为低风险的 23 名患者中,有 20 名接受了青霉素过敏评估和口服挑战。其中 19 名(95%)患者的青霉素过敏标签被去除(图 1)。中位年龄为 7 岁(范围为 11 个月至 18 岁)。参与者总体上对风险分层和去标签评价较好,所有 3 项实施措施的评分均较高:可接受性(平均 4.55,±标准差 [STD] 0.65)、适宜性(平均 4.58,STD ± 0.6)和可行性(平均 4.51,STD ± 0.73)。按医务人员类型和提供者类型分层时,可接受性、适宜性和可行性的衡量指标仍然较高。
我们的研究结果为在住院儿童中系统实施青霉素过敏去标签策略提供了支持。